company background image
HCM logo

HUTCHMED (China) NasdaqGS:HCM Stock Report

Last Price

US$14.30

Market Cap

US$2.6b

7D

-3.8%

1Y

-15.1%

Updated

24 Dec, 2024

Data

Company Financials +

HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$2.6b

HCM Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details

HCM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for HCM from our risk checks.

My Notes

Capture your thoughts, links and company narrative

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£14.30
52 Week HighUK£21.92
52 Week LowUK£11.93
Beta0.74
1 Month Change-17.63%
3 Month Change-18.24%
1 Year Change-15.13%
3 Year Change-58.94%
5 Year Change-42.96%
Change since IPO5.93%

Recent News & Updates

Hutchmed Growing Sales By 64% In H1 2024

Aug 09

Recent updates

Hutchmed Growing Sales By 64% In H1 2024

Aug 09

Hutchmed Is Turning Profitable

Mar 20

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Oct 10

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Aug 09

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Aug 01

Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83

Jul 15

Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema

Jul 06

Hutchmed Roils Markets With Changing Of Its Guard, U.S. Delisting Threat

Mar 11

Shareholder Returns

HCMUS PharmaceuticalsUS Market
7D-3.8%0.6%-0.4%
1Y-15.1%10.0%24.8%

Return vs Industry: HCM underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: HCM underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is HCM's price volatile compared to industry and market?
HCM volatility
HCM Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: HCM has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: HCM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,970Wei-Guo Suwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM fundamental statistics
Market capUS$2.59b
Earnings (TTM)-US$41.97m
Revenue (TTM)US$610.81m

4.2x

P/S Ratio

-61.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM income statement (TTM)
RevenueUS$610.81m
Cost of RevenueUS$658.26m
Gross Profit-US$47.45m
Other Expenses-US$5.48m
Earnings-US$41.97m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin-7.77%
Net Profit Margin-6.87%
Debt/Equity Ratio10.9%

How did HCM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:37
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HUTCHMED (China) Limited is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiangqiao TongBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Alec StranahanBofA Global Research